- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00489164
Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions (DECODE)
November 10, 2008 updated by: Cordis Corporation
A Randomized Feasibility Study With the Sirolimus-Eluting BX Velocity Balloon-Expandable Stent in the Treatment of Diabetic Patients With Native Coronary Artery Lesions (DECODE)
The main objective of this study is to assess in-stent late lumen loss in diabetic patients with de novo native coronary lesions using the sirolimus-eluting Bx VELOCITYä stent as compared to the Bx VELOCITY balloon-expandable stent.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
83
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, China
- Queen Mary Hospital
-
-
-
-
-
Mumbai, India, 400 026
- Jaslok Hospital & Research Centre
-
New Delhi, India, 110 025
- Escorts Heart Institute & Research Centre
-
-
Delhi
-
New Delhi, Delhi, India, 110062
- Batra Hospital & Research Centre
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, India, 600006
- Apollo Hospital
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- National Heart Institute
-
-
-
-
-
Singapore, Singapore, 168752
- National Heart Center
-
-
-
-
California
-
La Jolla, California, United States, 92037
- Foundation for Cardiovascular Medicine
-
-
Florida
-
Orlando, Florida, United States, 32803
- Florida Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- St Luke's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient must be 18 years of age;
- Patients must be previously diagnosed with Type I or Type II diabetes with documented treatment with insulin or oral hypoglycemics by medical history. (Undocumented or newly diagnosed diabetics must have fasting plasma glucose of >/= 126 mg/dl or a 2h post-load value in the OGTT >/=200 mg/dl, confirmed on alternate days);
- Female of childbearing potential must have a negative pregnancy test and must plan to be on accepted method of contraception for 6 months after time of enrollment;
- Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
- Treatment of lesions in native coronary arteries requiring a maximum of three stents per patient. Multi-vessel treatment is permissible. Additional stents may be used for procedural complications such as dissections. Patients with additional lesions can be included only if the other lesions are not considered clinically significant and do not require treatment;
- Target lesion is >/=2.25 and </=3.0 in diameter (visual estimate);
- Individual lesions are >/=10 mm to </= 32 mm in length located in a native coronary artery;
- Target lesions are de novo lesions in native coronary vessels;
- Acceptable candidate for coronary artery bypass surgery (CABG);
- Target lesion stenosis is >50% and <100% (TIMI I) (visual estimate);
- Patient is willing to comply with the specified follow-up evaluation;
- Patient must provide written informed consent prior to the procedure using a form that is approved by the local Institutional Review Board.
Exclusion Criteria:
- Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
- Unprotected left main coronary disease with 50% stenosis;
- Significant (>/=50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
- Patients admitted for treatment of diabetic ketoacidosis >/= 2 times in the past six months (Brittle Diabetics);
- Intervention of another lesion has occurred within six months prior to index procedure;
- Have an ostial target lesion;
- Target lesion is in a saphenous venous graft.
- Target lesion is due to in-stent restenosis.
- Angiographic evidence of thrombus within target lesion;
- Calcified lesions which cannot be successfully predilated;
- Ejection fraction </=30%;
- Totally occluded vessel (TIMI 0 level);
- Impaired renal function (creatinine > 2.0 mg/dL);
- Target lesion has excessive tortuosity unsuitable for stent delivery and deployment;
- Pretreatment with devices other than balloon angioplasty (direct stenting is not allowed);
- Target lesion involves bifurcation including a side branch >/=2.5mm in diameter (either stenosis of both main vessel and major branch or stenosis of just major branch) that would require side branch stenting which is likely to occur if side branch is diseased and intended to be stented;
- Previous brachytherapy of target vessel;
- Recipient of heart transplant;
- Patient with a life expectancy less than 12 months;
- Known allergies to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, stainless steel, contrast agent or sirolimus, that cannot be medically managed;
- Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
- Currently participating in an investigational drug or another device study;
- Treatment with Metformin (glucophage) within 48 hours of angiogram.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
In-stent late lumen loss as measured by QCA at six months post-procedure. In-stent measurement is defined as the measurement within the stented segment.
Time Frame: 6 months post-procedure
|
6 months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days, 6 months and 1 year post-procedure
Time Frame: at 30 days, 6 months and 1 year post-procedure
|
at 30 days, 6 months and 1 year post-procedure
|
Target lesion revascularization (TLR) and target vessel revascularization (TVR) at 30 days, 6 months and 1 year post-procedure
Time Frame: at 30 days, 6 months and 1 year post-procedure
|
at 30 days, 6 months and 1 year post-procedure
|
Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 30 days, 6 months and 1 year post-procedure
Time Frame: at 30 days, 6 months and 1 year post-procedure
|
at 30 days, 6 months and 1 year post-procedure
|
Device success defined as achievement of a final residual diameter stenosis of <50% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used
Time Frame: Throughout study
|
Throughout study
|
Lesion success defined as the attainment of <50% residual stenosis (by QCA) using any percutaneous method
Time Frame: Throughout study
|
Throughout study
|
Procedure success defined as achievement of a final diameter stenosis of <50% (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay
Time Frame: Throughout study
|
Throughout study
|
In-stent mean percent diameter stenosis (%DS), Binary restenosis and late lumen loss as measured by quantitative coronary angiography at post-procedure and at 6-months
Time Frame: at post-procedure and at 6-months
|
at post-procedure and at 6-months
|
In-lesion mean percent diameter stenosis (%DS), mean lumen diameter (MLD), binary restenosis and late lumen loss as measured by quantitative coronary angiography at post-procedure and at 6-months
Time Frame: at post-procedure and at 6-months
|
at post-procedure and at 6-months
|
Glycemic control as measured by HbA1C at 6 months and 1 year follow-up
Time Frame: at 6 months and 1 year follow-up
|
at 6 months and 1 year follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maurice Buchbinder, MD, Scripps Memorial Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Study Completion (Actual)
May 1, 2004
Study Registration Dates
First Submitted
June 20, 2007
First Submitted That Met QC Criteria
June 20, 2007
First Posted (Estimate)
June 21, 2007
Study Record Updates
Last Update Posted (Estimate)
November 11, 2008
Last Update Submitted That Met QC Criteria
November 10, 2008
Last Verified
November 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Vascular Diseases
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- P02-6316, P01-6311
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Diseases
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Alucent BiomedicalCompletedPeripheral Arterial Disease | Peripheral Vascular Diseases | Catheterization, PeripheralUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
Clinical Trials on Sirolimus-Eluting BX Velocity Balloon-Expandable Stent
-
Cordis CorporationCompletedCoronary Artery DiseaseItaly
-
Cordis CorporationCompletedCoronary Artery DiseaseGermany
-
Cordis CorporationCompletedCoronary Artery DiseaseUnited States
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
-
Cordis CorporationUnknownCoronary Artery Disease | Coronary AtherosclerosisUnited States
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Cordis CorporationCompletedCoronary Artery DiseaseGermany
-
Cordis CorporationCompletedCoronary Artery DiseaseBrazil
-
Korea University Guro HospitalCompletedAtherosclerosis | Peripheral Artery DiseaseKorea, Republic of
-
StentysTerminatedAcute Myocardial InfarctionNetherlands, United States